The effect of Saccharomyces boulardii supplementation on Helicobacter pylori eradication in children: a systematic review and meta-analysis of randomized controlled trials.
Liu LH, Han B, Tao J, Zhang K
Published in BMC Infectious Diseases
Methodology
Meta-analysis of 15 RCTs of S. boulardii added to standard triple therapy in children
Key Findings
Eradication 87.7% vs 75.9% (RR 1.14, 95% CI 1.10-1.19); total adverse events 9.2% vs 29.2% (RR 0.32) and diarrhea 14.7% vs 32.4% (RR 0.46).
Conclusions
S. boulardii added to triple therapy improves eradication and markedly reduces treatment-related adverse events in children.
Limitations
Pediatric populations only; many included trials from a single region and of moderate methodological quality.
Supplements Studied
S. boulardii in combination with STT was more effective than STT alone (intention-to-treat analysis: 87.7% vs. 75.9%, RR = 1.14, 95% CI: 1.10-1.19, P < 0.00001).
S. boulardii in combination with STT was more effective than STT alone (intention-to-treat analysis: 87.7% vs. 75.9%, RR = 1.14, 95% CI: 1.10-1.19, P < 0.00001).
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.